IMPORTANT SAFETY INFORMATIONPRESCRIBING INFORMATION

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

Dose modifications for hematologic toxicities1

  • In the case of hematologic toxicity, doses of FOLOTYN may be omitted or reduced
  • Prior to administering FOLOTYN:
    • Platelet count should be ≥100,000/mcL for first dose and ≥50,000/mcL for all subsequent doses
    • ANC should be ≥1,000/mcL
  • Omitted doses will not be made up at the end of the cycle; once a dose reduction occurs for toxicity, do not re-escalate
Dose modifications for hematologic toxicities

ANC: absolute neutrophil count
G-CSF: granulocyte colony-stimulating factor
GM-CSF: granulocyte macrophage colony-stimulating factor

References:

  • FOLOTYN Prescribing Information. Allos Therapeutics, Inc. 2012.